Dextrmetomidine assisted the withdrawal of short-acting benzodiazepines:a pilot study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300067496

Enrollment

Unknown

Registered

2023-01-10

Start date

2023-01-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug addiction

Interventions

Intervention group:Stop using BZDs and use oral diazepam. At 22:00 at night, receive intravenous infusion of dexmedetomidine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-65; (2) Meet the ICSD-3 diagnostic criteria for chronic insomnia; (3) Take large doses of short-acting benzodiazepines every day for more than 1 month; (4) Willing to reduce and stop short-acting benzodiazepines; (5) Volunteer to participate in the study and sign the informed consent form;

Exclusion criteria

Exclusion criteria: (1) History of hypertension, hypotension and bradycardia; (2) Heart, lung, liver and kidney dysfunction; (3) Uncontrolled anxiety, depression and/or mental disorder; (4) Sleep apnea hypopnea syndrome, restless leg syndrome and other sleep disorders; (5) Pregnancy or lactation; (6) Allergy to the study drug;

Design outcomes

Primary

Measure	Time frame
Success rate of drug withdrawal;Drug withdrawal speed;	—

Secondary

Measure	Time frame
Re-administration rate after drug withdrawal;Insomnia severity index;	—

Countries

China

Contacts

Public ContactLi Qifang

Floor 9, No. 1279, Sanmen Road, Shanghai

liqifang2004@126.com13774452061

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026